New Developments in Hepatitis C

References

• Choo Q-L, Kuo G, Weiner A J, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 259–62
   Google Scholar
• Choo Q-L, Richman K H, Han J H, et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci 1991; 88: 2451–5
   PubMed Web of Science ®Google Scholar
• Kato N, Hijikata M, Ootsuyama, et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci 1990; 87: 9524–8
   PubMed Web of Science ®Google Scholar
• Takamizawa A, Mori C, Fuke I, et al. Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol 1991; 65: 1105–13
   PubMed Web of Science ®Google Scholar
• Ogata N., Alter H J, Miller R, et al. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci 1991; 88: 3392–6
   PubMed Web of Science ®Google Scholar
• Miller R H, Purcell R H. Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups. Proc Natl Acad Sci 1990; 87: 2057–61
   PubMed Web of Science ®Google Scholar
• Enomoto N, Takada A, Nakao T, et al. There are two major types of hepatitis C virus in Japan. Biochem Biophys Res Com-mun 1990; 170: 1021–5
   PubMedGoogle Scholar
• Okamoto H, Kurai K, Okada S-I, et al. Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: comparative study of four distinct genotypes. Virology, 2(188)331–41
   Google Scholar
• Han J, Shyamala V, Richman K H, et al. Characterization of the terminal regions of hepatitis C viral RNA: identification of conserved sequences of the 5′ untranslated region and poly(A) tails at the 3′ end. Proc Natl Acad Sci 1991; 88: 1711–5
   PubMed Web of Science ®Google Scholar
• Weiner A J, Brauer M J, Rosenblatt J, et al. Variable and hy-pervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991; 180: 842–8
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Kubo Y, Boonmar S, et al. The putative nucleo-capsid and envelope protein genes of hepatitis C virus determined by comparison of the nucleotide sequences of two isolates derived from an experimentally infected chimpanzee and healthy human carriers. J Gen Vir 1990; 71: 3027–33
   PubMedGoogle Scholar
• Okamoto H, Okada S, Sugiyama Y, et al. The 5′terminal sequence of the hepatitis C virus genome. Jpn J Exp Med 1990; 60: 167–77
   PubMedGoogle Scholar
• Takeuchi K, Boonmar S, Kubo Y, et al. Hepatitis C viral cDNA clones isolated from a healthy carrier donor implicated in posttransfusion non-A, non-B hepatitis. Gene 1990; 91: 287–91
   PubMedGoogle Scholar
• Cuypers H TM, Winkel I N, van der Poel C L, et al. Analysis of genomic variability of hepatitis C virus. J Hepatol 1991; 13: S15–9
   Google Scholar
• van der Poel C L, Reesink H W, Lelie P N, et al. Anti-hepatitis C antibodies and non-A, non-B post-transfusion hepatitis in the Netherlands. Lancet 1989; 2: 297–8
   PubMed Web of Science ®Google Scholar
• Kuo G, Choo Q-L, Alter H J, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362–4
   PubMed Web of Science ®Google Scholar
• van der Poel C L, Reesink H W, Schaasberg W, et al. Infectivity of blood seropositive for hepatitis C virus antibodies. Lancet 1990; 335: 558–60
   PubMed Web of Science ®Google Scholar
• van der Poel C L, Bresters D, Reesink H W, et al. Early anti-hepatitis C virus response with second-generation C200/C22 ELISA. Vox Sang 1992; 62: 208–12
   PubMed Web of Science ®Google Scholar
• Bresters D, Cuypers H TM, Reesink H W, et al. Enhanced sensitivity of a second generation ELISA for antibody to hepatitis C virus. Vox Sang 1992; 62: 213–7
   PubMedGoogle Scholar
• van der Poel C L, Cuypers H TM, Reesink H W, et al. Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet 1991; 337: 317–9
   PubMed Web of Science ®Google Scholar
• Weiner A J, Kuo G, Bradley D W, et al. Detection of hepatitis C viral sequences in non-A, non-B hepatitis. Lancet 1990; 335: 1–3
   PubMed Web of Science ®Google Scholar
• Sugitani M, Inchauspe G, Shindo M, Prince A M. Sensitivity of serological assays to identify blood donors with hepatitis C viraemia. Lancet 1992; 339: 1018–9
   PubMedGoogle Scholar
• Bresters D, Cuypers H TM, Reesink H W, et al. Detection of hepatitis C viral RNA sequences in fresh and paraffin-embedded liver biopsy specimens of non-A, non-B hepatitis patients. J Hepatol 1992; 15: 391–5
   PubMedGoogle Scholar
• Bresters D, Mauser-Bunschoten E P, Cuypers H TM, et al. Disappearance of hepatitis C virus RNA in plasma during interferon alpha-2B treatment in hemophilia patients. Scand J Gastroenterol 1992; 27: 166–8
   PubMed Web of Science ®Google Scholar
• Alter H J, Purcell R H, Shih J W, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321: 1495–1500
   Google Scholar
• Tremolada F, Casarin C, Tagger A, et al. Antibody to hepatitis C virus in post-transfusion hepatitis. Ann Intern Med 1991; 263: 277–81
   Google Scholar
• van der Poel C L, Cuypers H TM, Reesink H W, et al. Risk factors in HCV infected blood donors. Transfusion 1991; 31: 777–9
   PubMed Web of Science ®Google Scholar
• Esteban J I, Lopez-Talavera J C, Genesca J, et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991; 115: 443–9
   PubMed Web of Science ®Google Scholar
• Tremolada F, Benvegno L, Casarin C, et al. Antibody to hepatitis C virus in hepatocellular carcinoma. Lancet 1990; 335: 300–1
   Google Scholar
• Kiyosawa K, Soderyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671–5
   PubMed Web of Science ®Google Scholar
• Nishioka K, Watanabe J, Furuta S, et al. A high prevalence of antibody to hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 1991; 67: 429–33
   PubMedGoogle Scholar
• Michel G, Ritter A, Gerken G, et al. Anti-GOR and hepatitis C virus immune liver diseases. Lancet 1992; 339: 267–9
   PubMed Web of Science ®Google Scholar
• Manns M P, Griffin K J, Sullivan K F, Johnson E F. LKM-1 autoantibodies recognize a short linear sequence in P450IIF6, a cytochrome P-450 monooxygenase. J Clin Invest 1991; 88: 1370–8
   PubMed Web of Science ®Google Scholar
• Melbye M, Biggar R J, Wantzin P, et al. Sexual transmission of hepatitis C virus: cohort study (1981-9) among European homosexual men. Br Med J 1990; 301: 210–2
   PubMed Web of Science ®Google Scholar
• Reesink H W, Wong V CW, Ip H MH, et al. Mother-to-infant transmission and hepatitis C virus. Lancet 1990; 335: 1216–7
   PubMed Web of Science ®Google Scholar
• Thaler M M, Park Ch-K, Landers D V, et al. Vertical transmission of hepatitis C virus. Lancet 1991; 338: 17–8
   PubMed Web of Science ®Google Scholar
• van der Poel C L, Reesink H W, Mauser-Bunschoten E P, et al. Prevalence of anti-HCV antibodies confirmed by recombinant immunoblot in different population subsets in the Netherlands. Vox Sang 1991; 91: 30–6
   Google Scholar
• Esteban J I, Esteban R, Viladomiu, et al. Hepatitis C virus antibodies among risk groups in Spain. Lancet 1989; 2: 294–6
   PubMed Web of Science ®Google Scholar
• Davis G L, Balart R A, Schiff E R, et al. Treatment of chronic hepatitis C with recombinant interferon alpha. N Engl J Med 1989; 321: 1502–6
   Google Scholar
• di Bisceglie A M, Martin P, Kassianides C, et al. Recombinant interferon alpha therapy for chronic hepatitis C. N Engl J Med 1989; 321: 1506–10
   PubMed Web of Science ®Google Scholar
• Saez-Rouyela F, Porres J C, Moreno A, et al. High doses of recombinant alpha interferon or gamma interferon for chronic hepatitis C: A randomized, controlled trial. Hepatology 1991; 13: 327–31
   PubMedGoogle Scholar
• Marcellin P, Colin J-F, Boyer N, et al. Fatal exacerbation of chronic hepatitis B induced by recombinant alpha-interferon. Lancet 1991; 338: 828
   PubMedGoogle Scholar
• Wandl U B, Kloke O, Niederle N. Liver failure due to recombinant alpha interferon for chronic myelogenous leukaemia. Lancet 1992; 339: 123–4
   PubMedGoogle Scholar